Wyatt, M.; Quinn, A.; Shade, L.; McGarry, M.
Refining CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Diagnosis: Impact of CFTR2 Variant Classifications. Int. J. Neonatal Screen. 2025, 11, 60.
https://doi.org/10.3390/ijns11030060
AMA Style
Wyatt M, Quinn A, Shade L, McGarry M.
Refining CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Diagnosis: Impact of CFTR2 Variant Classifications. International Journal of Neonatal Screening. 2025; 11(3):60.
https://doi.org/10.3390/ijns11030060
Chicago/Turabian Style
Wyatt, MacKenzie, Alexandra Quinn, Lincoln Shade, and Meghan McGarry.
2025. "Refining CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Diagnosis: Impact of CFTR2 Variant Classifications" International Journal of Neonatal Screening 11, no. 3: 60.
https://doi.org/10.3390/ijns11030060
APA Style
Wyatt, M., Quinn, A., Shade, L., & McGarry, M.
(2025). Refining CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID) Diagnosis: Impact of CFTR2 Variant Classifications. International Journal of Neonatal Screening, 11(3), 60.
https://doi.org/10.3390/ijns11030060